secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K/A
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001171843-26-000405
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close
--------------------------------------------------------------------------------

- Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.
- Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.
- On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/0001171843-26-000405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000405/f8ka_012226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer